Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisavanbulin Phase 1/2a in Advanced Solid Tumors or Recurrent Glioblastoma
NCT02895360Phase 2Completed
- Sponsor
- Basilea Pharmaceutica
- Start
- Aug 2016
- Primary completion
- Aug 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lisavanbulin in solid tumor, glioblastoma (GBM), ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Basilea Pharmaceutica. Started Aug 2016; status: completed.
02
Drugs
lisavanbulin
03
Conditions
solid tumorglioblastoma (GBM)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02895360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02895360.